Daily Stock Pick â€” January 23, 2026

FOLD â€“ Amicus Therapeutics

News: BioMarin agreed to acquire Amicus for $14.50/share with expected Q2 2026 close; Amicus also posted GAAP-profitable Q3â€™25 with doubleâ€‘digit revenue growth. ([investors.biomarin.com](https://investors.biomarin.com/news/news-details/2025/BioMarin-to-Acquire-Amicus-Therapeutics-for-4-8-Billion-Expanding-Position-as-a-Leader-in-Rare-Diseases-Accelerating-Revenue-Growth-and-Strengthening-Financial-Outlook/default.aspx?utm_source=openai))

Score (0â€“1000): 735

ADVICE: Strong Buy

Certainty: 74%

Forecast image URL: https://stockscan.io/stocks/FOLD/forecast

Verifier note: Low-risk merger-arb upside into expected close + improving fundamentals (2024 revenue +33% YoY; positive GAAP in H2â€™25; ~$264M cash) and no recent dilution flagged; capped downside given cash-flowing assets. Sources: investors.biomarin.com; ir.amicusrx.com; gurufocus.com. ([investors.biomarin.com](https://investors.biomarin.com/news/news-details/2025/BioMarin-to-Acquire-Amicus-Therapeutics-for-4-8-Billion-Expanding-Position-as-a-Leader-in-Rare-Diseases-Accelerating-Revenue-Growth-and-Strengthening-Financial-Outlook/default.aspx?utm_source=openai))

---
**Legend**
ğŸŸ¢ğŸŸ¢ğŸŸ¢ **Ultra Strong Buy** â€” Score > 800 â†’ â€œGuaranteed high returnâ€
ğŸŸ¢ **Strong Buy** â€” Score > 700 â†’ â€œAmazing Chancesâ€
ğŸŸ¡ **Buy** â€” Score â‰ˆ 600 â†’ â€œGreat Chancesâ€
ğŸ”´ **Ignore** â€” Score < 599 â†’ â€œIgnoreâ€

